Participant flow

Celebrex (Celecoxib) Treatment of Laryngeal Papilloma · Source last updated 2012-08-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   once-time routine surgery with (either of CO2 laser at continue model and 10.0-20.0 W, or "cold" surgery with micro-instruments), in 15 subjects

   id

   FG000

   title

   Control

2. description

   once-time PDL surgery at 6.0-8.0 W, followed by oral taking of Celecoxib (100mg,BID)for 9 months

   id

   FG001

   title

   Experimental

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         3

      type

      Lost to Follow-up

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         8

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         5

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         3

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Many patients, who were eligible for this study, finally declined to participate this study due to a safety concern with Celebrex

recruitment Details

3 years

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice